Lenvatinib 10mg capsule

• Lenvima 10mg is also known as tyrosine kinase inhibitor.
• Lenvima 10mg targets something to the cancer cells.
• Lenvima 10mg capsule is well absorbed. In which Food does not affect the range of absorption but lower the rate.
• Lenvima 10mg  which is a prescription drug used under proper guidance of medical oncologist.

INDICATION

• Indicated For the treatment of thyroid cancer which cannot be treated with radioactive iodine.
• Indicated By combined with everolimus to treat the advanced renal carcinoma in which other drugs failed to be effective.
• Indicated For the treatment of hepatocellular primary liver cancer

DOSAGE

• The recommended dose of differentiated thyroid cancer is Lenvatinib 24 mg, it administers by two 10mg and one 4 mg capsules taken orally, once in a day along with or without food.
• The recommended dose of renal cell carcinomas is Lenvatinib 18 mg, given as one 10mg capsule and two 4 mg capsules administrated in combination with 5mg everolimus orally taken once in a day with or without food.
• The recommended dose of first-line treatment of unresectable hepatocellular carcinoma is based on actual body weight
• If < 60 kg then 8mg PO qDay
• If ≥ 60 kg then 12mg PO qDay

Administration :

• Lenvima 10mg capsule  must take at same time each day
• Follow the drug till disease progression.
• Lenvima 10mg capsule  must swallowed whole.
• In a small glass of liquid dissolved the capsules
• In 1 tablespoon apple juice or water and embed the capsules into the liquid without breaking or crushing them.
• Dip the capsules in the liquid for at least 10 minutes.
• The liquid is agitated for at least 3 minutes. Drink the mixture.
• Add 1 tablespoon of water or apple juice to the glass after drinking the mixture
• Mix up the contents a few times and swallow the additional liquid.

OVERDOSAGE: 

• Lenvima 10mg has no individual antitoxin for overdose. Since high plasma protein binding.  Lenvima 10mg capsule  is not expected to be dialyzable. Take the patients to emergency medical department or call poison control helpline.

MECHANISM

Lenvima 10mg called as targeted therapy. In which it aims something particular to the cancer cells, hence reduces side effects caused by repairing to the healthy cells. Lenvima 10mg mechanism by inhibiting two processes which allow cancer cells to develop

• Prevention of a protein that promotes cell division
• Stopping the VEGF receptor, which is necessary for angiogenesis, or the growth of a blood supply to the tumor. This discard the tumor’s source of nutrients.

ADME

• Maximum plasma concentration is 1 to 4 hours post dose.
• Effect with food is low to the extent of absorption.
• Human plasma proteins bounding about 98% to 99%.
• Metabolized in CYP3A and aldehyde oxidase. Lenvatinib metabolic pathway is identified as enzymatic and non-enzymatic processes.
• The drug excreted via 64% feces and 25% urine,
• The terminal half-life of Lenvatinib is 28 hours.

PRECAUTION

• When using Lenvima 10mg Hypertension reslted in 73% of Lenvatinib-treated patients in clinical trials (grade 3 hypertension was 44%); regulate blood pressure before to treatment; check blood pressure after 1 week, then q2weeks for the first 2 months.
• Lenvima 10mg causes Arterial thromboembolic events occurred in 5% of treated patients; stop drug following a thromboembolic event; forever stop treatment following an arterial thrombotic event.
• When using of  Lenvima 10mg capsule will occurs Gastrointestinal perforation or fistula (2%); stop if patient experience a GI perforation or life-threatening fistula; permanently stop therapy in patients who have gastrointestinal perforation of any serious or Grade 3 or 4 fistula.
• While on treatment will reported Serious complications of poorly controlled hypertension.
• Discuss with the doctor if you are breastfeeding or plan to breastfeed. Avoid breastfeed during Lenvima 10mg treatment.

MISSED DOSE

• The dose of Lenvima 10mg is missed, and then takes the dose as you remember earlier. If time to next dose reaches, then swap the missed dose and continue the routine schedule. Avoid taking 2 doses at one time. Please consult your doctor for further clarification

STORAGE

• Store the drug at 2 ℃ – 8 ℃
• Avoid freezing or shake
• Protect from light

SIDE EFFECTS

Common side effects :

• Weight reduced
• Palmar-plantar erythrodysesthesia
• Protein urea
• Hand-foot syndrome
• Dyspnea
• Loss of appetite
• Difficulty speaking
• Heartburn
• Blood pressure increased
• Diarrhea
• Muscle aches
• Mouth sores
• Insomnia
• Dental & oral infection
• Taste changes
• Swelling
• Nose bleed
• Urinary tract infection
• Hair loss
• Taste changes
• Rash

CONTACT DETAILS

Phone : 9987711567

Email : applepharmaceutical@gmail.com

Email : info@myapplepharma.com

Website : https://myapplepharma.com/lenvatinib-10mg.php

https://myapplepharma.com/lenvatinib.php

Lenvatinib 4mg Capsule

• Lenvima 4mg is also known as tyrosine kinase inhibitor.
• Lenvima 4mg targets something to the cancer cells.
• Lenvima 4mg is well absorbed. In which Food does not affect the range of absorption but lower the rate.
• Lenvima 4mg which is a prescription drug used under proper guidance of medical oncologist.

INDICATION

• Indicated For the treatment of thyroid cancer which cannot be treated with radioactiveiodine.
• Indicated By combined with everolimus to treat the advanced renal carcinoma in which other drugs failed to be effective.
• Indicated For the treatment of hepatocellular primary liver cancer

DOSAGE

• The recommended dose of differentiated thyroid cancer is Lenvatinib 24 mg, it administers by two 10mg and one 4 mg capsules taken orally, once in a day along with or without food.
• The recommended dose of renal cell carcinomas is Lenvatinib 18 mg, given as one 10mg capsule and two 4 mg capsules administrated in combination with 5mg everolimus orally taken once in a day with or without food.
• The recommended dose of first-line treatment of unresectable hepatocellular carcinoma is based on actual body weight
• If < 60 kg then 8mg PO qDay
• If ≥ 60 kg then 12mg PO qDay

Administration :

• Lenvima 4mg capsule must take at same time each day
• Follow the drug till disease progression.
• Lenvima 4mg capsule must swallowed whole.
• In a small glass of liquid dissolved the capsules
• In 1 tablespoon apple juice or water and embed the capsules into the liquid without breaking or crushing them.
• Dip the  Lenvima 4mg capsule in the liquid for at least 10 minutes.
• The liquid is agitated for at least 3 minutes. Drink the mixture.
• Add 1 tablespoon of water or apple juice to the glass after drinking the mixture
• Mix up the contents a few times and swallow the additional liquid.

OVERDOSAGE

Lenvima 4mg has no individual antitoxin for overdose. Since high plasma protein binding.  Lenvima 4mg is not expected to be dialyzable. Take the patients to emergency medical department or call poison control helpline.

MECHANISM

Lenvatinib called as targeted therapy. In which it aims something particular to the cancer cells, hence reduces side effects caused by repairing to the healthy cells. Lenvatinib mechanism by inhibiting two processes which allow cancer cells to develop

• Prevention of a protein that promotes cell division
• Stopping the VEGF receptor, which is necessary for angiogenesis, or the growth of a blood supply to the tumor. This discard the tumor’s source of nutrients.

ADME

• Maximum plasma concentration is 1 to 4 hours post dose.
• Effect with food is low to the extent of absorption.
• Human plasma proteins bounding about 98% to 99%.
• Metabolized in CYP3A and aldehyde oxidase.  Lenvima 4mg metabolic pathway is identified as enzymatic and non-enzymatic processes.
• The drug excreted via 64% feces and 25% urine,
• The terminal half-life of Lenvima 4mg is 28 hours.

PRECAUTION

• When using Lenvima 4mg Hypertension reslted in 73% of Lenvatinib-treated patients in clinical trials (grade 3 hypertension was 44%); regulate blood pressure before to treatment; check blood pressure after 1 week, then q2weeks for the first 2 months.
• Lenvima 4mg causes Arterial thromboembolic events occurred in 5% of treated patients; stop drug following a thromboembolic event; forever stop treatment following an arterial thrombotic event.
• When using of  Lenvima 4mg capsules will occurs Gastrointestinal perforation or fistula (2%); stop if patient experience a GI perforation or life-threatening fistula; permanently stop therapy in patients who have gastrointestinal perforation of any serious or Grade 3 or 4 fistula.
• While on treatment will reported Serious complications of poorly controlled hypertension.
• Discuss with the doctor if you are breastfeeding or plan to breastfeed. Avoid breastfeed during Lenvatinib 4mg treatment.

MISSED DOSE

• The dose of  Lenvima 4mg is missed, and then takes the dose as you remember earlier. If time to next dose reaches, then swap the missed dose and continue the routine schedule. Avoid taking 2 doses at one time. Please consult your doctor for further clarification

STORAGE

• Store the drug at 2 ℃ – 8 ℃
• Avoid freezing or shake
• Protect from light

SIDE EFFECTS

Common side effects :

• Weight reduced
• Palmar-plantar erythrodysesthesia
• Protein urea
• Hand-foot syndrome
• Dyspnea
• Loss of appetite
• Difficulty speaking
• Heartburn
• Blood pressure increased
• Diarrhea
• Muscle aches
• Mouth sores
• Insomnia
• Dental & oral infection
• Taste changes
• Swelling
• Nose bleed
• Urinary tract infection
• Hair loss
• Taste changes
• Rash

CONTACT DETAILS

Phone : 9987711567

Email : applepharmaceutical@gmail.com

Email : info@myapplepharma.com

Website : https://myapplepharma.com/lenvatinib-4mg.php

https://myapplepharma.com/lenvatinib.php

• Revolade 25mg is a prescription drug which is used under the guidance of the doctor.
• Revolade 25mg drug may be used as part of a combination therapy. Thereby drug may need to take it with other medications.

INDICATION

Revolade 25mg is mainly indicated for the treatment of patients having :

• Reduced platelet levels due to chronic immune thrombocytopenia
• Reduced platelet counts due to chronic hepatitis C virus infection

Severe aplastic Anemia :

• First line treatment of severe aplastic Anemia
• Treatment of refractory severe aplastic Anemia

DOSAGE

Chronic Immune Thrombocytopenia :

• Indicated only in patients with chronic immune thrombocytopenia whose clinical condition increases bleeding risk

Initial : 50 mg PO qDay

• Adjust dose to achieve and control platelet count (Plt) >50 x 10^9/L to lowers risk of bleeding; not to exceed 75 mg/day Chronic Hepatitis C-associated Thrombocytopenia

Initial : 25 mg PO qDay

• Dose is Adjust in 25 mg accretion q2weeks PRN to attain target Plt needed to start/control antiviral therapy with pegylated interferon and ribavirin; not to exceed 100 mg/day
• During antiviral therapy, regulate dose to stop dose reductions of peginterferon
• Severe Aplastic Anemia

First-line therapy :

• Concomitant use with standard immunosuppressive therapy, for patients with serious aplastic Anemia (SAA)
• Usual dose: 150 mg PO qDay for 6 months
• Do not give more than starting dose; total duration is 6 months

Refractory SAA :

• The drug given for this condition who fail to respond sufficient to at least 1 before immunosuppressive therapy
• Usual dose: 50 mg PO qDay
• Adjust dose in 50-mg accretion q2Weeks PRN to attain target Plt ≥50 x 10^9/L as required; not exceed 150 mg/day; may take up to 16 weeks for hematologic response.

MECHANISM

• Revolade 25mg be part of class of drugs called thrombopoietin (TPO) receptor agonists. A classification of drugs is a association of medications which work in a similar way. These drugs are often used to treat similar conditions. Revolade works by raise cells in bone marrow and leads these cells to make various platelets. This effect reduces the risk of bleeding.

ADME

Absorption:

• Peak plasma concentration is 2-6 hours

Distribution:

• Highly human plasma protein bounding is >99% and in blood plasma level is 50% to 79%

Metabolism:

• Predominantly metabolised through cleavage, oxidation and conjugation with glucuronic acid.

Elimination:

• Revolade 25mg tablet eliminated primarily via feces 59%, along with 31% via renally excreted
• Half-life of Revolade 25mg healthy patients is 21-23 hours and idiopathic thrombocytopenic purpura is 26-35 hours.

PRECAUTION

• Revolade 25mg causes warning condition, call the doctor while new medication interaction Disease progression warning: Avoid using the drug while the patients have myelodysplastic syndrome (MDS), will increases the risk of death.
• If other blood clot risk factors, then avoid Revolade 25mg because it will increase platelet counts and blood clots.
• If the patients have cataracts, avoid Revolade 25mg due to the drug effects cataracts and make the condition worse.

DRUG INTERACTION

• Revolade 25mg tablet interaction with these drugs ezetimibe, glyburide, Olmesartan, repaglinide, valsartan, imatinib, irinotecan, lapatinib, methotrexate, mitoxantrone, Bosentan, sulfasalazine, and topotecan irinotecan leads increase of side effects. hence the doctor may reduce your dosage of these drugs if required.
• Revolade 25mg co administration with Cholesterol-reducing drugs like atorvastatin, fluvastatin, rosuvastatin, pravastatin, and simvastatin, pitavastatin. Have high side effects can contains muscle pain. The doctor may reduce the dosage of your cholesterol drugs.
• Revolade 25mg tablet concomitant use with Antacids, vitamins, or supplements which involves Ca, Al, Fe, Se, Zn, or Mg. To stop interactions, then take Revolade two hours before or four hours after administrating any of these products.

STORAGE

• Store at room temperature 20℃ and 25℃.
• Discard the left-out medicine if not used within 30 minutes

MISSED DOSE

• In case of missed dose, patients must consult with medical practitioner and follow the instructions given by them. thereby missed dose should be avoid and follow the regular dosing schedule.

SIDE EFFECTS

Common side effects :

• low red blood cells
• nausea
• fever
• weakness
• pain in head
• cough
• decreased appetite
• flu
• diarrhoea

Serious side effects :

• Urine in dark colour
• Yellowing of your skin
• Abdomen swelling
• Confusion
• Chest pain
• Dyspnea
• Cloudy vision
• Sensitivity to light
• Seeing circles around lights
• Swelling of legs.

CONTACT DETAILS

Phone : 9987711567

Email : applepharmaceutical@gmail.com

Email : info@myapplepharma.com

Website : https://myapplepharma.com/eltrombopag-25mg.php

https://myapplepharma.com/eltrombopag.php

• Xtandi 40mg is a hormonal therapy used for advanced prostate cancer treatment, like for 0men who are all affected with prostate carcinoma in metastatic stage.
• These are majorly indicated for prostate carcinoma, which contains Enzalutamide, as an active component considered as non steroidal anti-androgen medication. It is involved in association with castration in the therapy of metastatic or long lasting castration resistant prostate cancer. It is a prescribing medicine, the main ingredient which is used as enzalutamide, only prescribed by medical oncologist.

XTANDI DOSING CONDITIONS AND ADMINISTRATION

• The usual prescribed dosage of Xtandi is 160mg as a single dose by taking with or without food. Xtandi 40mgis available in the strength of 40mg; four Capsules of Xtandi 40mgshould be administered at a same time.
• Xtandi 40mg Capsule should not crush, not chew taken with glass of water. Xtandi Dosing adjustment: In patients with ≥ grade III toxicity: Xtandi 40mg therapy should be refuse for one week or the symptoms should be reduced to grade II, then restart with same dose or decreased to 80mg or 120mg Strong CYP2C8 inhibitors
• While combining with Xtandi 40mg Capsule, the dosage should be modified by reducing to 80mg as a single dose or avoid this combination. Strong CYP3A4 inducers: Co administration of Xtandi 40mg with Strong CYP3A4 inducers, xtandi dosage increased up to 240mg or stop this combination.

MECHANISM

• An androgen which is a male hormone is used to develop prostate carcinoma. One of the major hormone secreted by testes and adrenal glands is known as testosterone.
• Xtandi 40mg containing Enzalutamide will interfere with testosterone production, causes tumor cell growth depletion. It interfere with androgen receptor signaling transduction and leads to cancer cellulysis

PHARMACOKINETICS

Absorption :

• After receiving 160mg of Xtandi 40mg for mCRPC, from median time to attain peak plasma concentration time at 1 hour (variation with 0.5 to 3 hours). The steady state level of Xtandi 40mg Capsule is accomplished by day 28 Food does not cause any alteration in absorption of Xtandi 40mg Capsules.

Distribution :

• Volume of distribution 110L High plasma protein bounding capacity of Xtandi 40mgCapsules is occurs as 97% to 98%

Metabolism:

• Two most prominent cytochrome isoenzymes are involved in metabolism of Xtandi 40mg Capsule. There are two isoenzymes i.e CYP2C8 & CYP3A4; in which CYP2C8 is vital for production of N-desmethyl Enzalutamide which is an active metabolite of Enzalutamide.

Excretion :

• Xtandi 40mg Capsuleundergoes excretion by hepatic metabolism .

Elimination :

• 71% in urine; 14% in feces The terminal half life period of  Xtandi 40mg Capsule. Capsules is 5.8 days (range at 2.8 to 10.2 days); N-desmethyl Enzalutamide has half life period of relatively 7.8 to 8.6 days.

WARNING AND PRECAUTIONS

• During the treatment with Xtandi 40mgCapsules, patient may suffer with some adverse effects like; Posterior reversible encephalopathy syndrome Seizures In PRES, some neurological disorders occur in patients.
• The condition can recovered by providing safety measures or discontinue the therapy as soon as possible. PRES is recognized by using MRI In seizures, Before starting the treatment patient must counsel about this adverse reaction and Stop the therapy if possible.
• Spermatogenesis occurs that may prohibit the male fertility leads to hypo spermatogenesis. In androgen decline the treatment, may have increase exposure of cardiovascular disease like worsening hypertension.

Pregnancy :

• Pregnancy category of Xtandi 40mgCapsule is D Xtandi40mgis contraindicated to pregnancy; it may cause fetal harm even to death.

Lactation

• Breast feeding is not suggested, Xtandi 40mgis contraindicated in lactation

MISSED DOSE

• Xtandi 40mgis a chemical drug, used in prostate cancer. Xtandi 40mgCapsule should not be self medicated, used by the patients only after getting advice from the medical oncologist.
• If a single dose missed by patient, then must consult with the physician and follow the instructions as per the guidance of medical adviser, the missed dose should be taken within a time or avoid the missed dose and follow the regular schedule.

DRUG INTERACTION

• Xtandi 40mginteract with some drugs like Xtandi 40mgdrug combined with CYP2C8 strong inhibitors, causes elevation of plasma concentration time curve of Enzalutamide and its active metabolite.
• So avoid this combination, otherwise dosage of Xtandi 40mgshould be reduced to 80mg. Xtandi with CYP2C8 strong inducers causes variation in plasma exposure of Xtandi, to minimize this problem to avoid this concomitant. Co administration of Xtandi Capsules with strong inhibitors or CYP3A4, leads to elevate the AUC of Enzalutamide and its metabolite. CYP3A4 strong inducers example like; phenytoin, Phenobarbital, carbamazepine etc combines with Xtandi40mg .
• Capsules causes depletes the plasma exposure of Xtandi. Moderate CYP3A4 inducers like Bosentan, efavirenz, modafinil, st Johns wort causes decreasing the plasma concentration of Xtandi Capsule. Xtandi 40mgCapsules are strong CYP3A4 inducers and moderate CYP2C8 & CYP2C19. CYP3A4 strong inducers like Midazolam, CYP2C8 inducers like warfarin, & CYP2C19 inducers like Omeprazole with Xtandi 40mgcauses reducing the plasma risk of Midazolam, warfarin & Omeprazole.

CONTRAINDICATION

• Xtandi 40mgCapsules are contraindicated to pregnancy condition, which may cause fetal harm leads to death. An Anaphylactic reaction happens, if patients are contraindicated to the ingredient present in Xtandi Capsules.

OVER DOSAGE

• In the case of over dosage of Xtandi Capsules, causes severe seizures. If occurring of over dosage , immediately discontinue the treatment and maintain the safety measures. In dose acceleration study at ≤ 240mg daily the condition seizure does not occur. If the dose of 360mg, 480mg & 600mg at high risk will causes Seizures

XTANDI SIDE EFFECTS

• Some side effects during the therapy using with Xtandi; Back pain, Arthralgia, Muscular weakness, pain, Diarrhea, Hypertension & hot flush, Dizziness, headache, Asthenia conditions, Peripheral edema, Spinal cord compression, paresthesia, Mental impairment, Hypesthesia, Respiratory tract infections, Hematuria, Pollakiuria, Dry skin, Pruritus, Neutropenia, Thrombocytopenia, Increasing bilirubin level, Epistaxis, Infections like sepsis, Fractures, joint injury, and hematomas (Fall associated injuries). Hallucinations.

CONTACT DETAILS

Phone : 9987711567

Email : applepharmaceutical@gmail.com

Email : info@myapplepharma.com

Website : https://myapplepharma.com/enzalutamide-40mg.php

https://myapplepharma.com/enzalutamide.php

• Enzamide 40mg is a hormonal therapy, for men who are all affected with prostate carcinoma in metastatic stage.
• Enzamide 40mg tablet are majorly indicated for prostate carcinoma, which contains Enzalutamide, as an active component considered as non steroidal anti-androgen medication. 
• Enzamide 40mg  is involved in association with castration in the therapy of metastatic or long lasting castration resistant prostate cancer. 
• Enzamide 40mg  is a prescription medicine, the main ingredient which is used as enzalutamide, only prescribed by medical oncologist.

CAPSULES INDICATIONS

The primary usage of  Enzamide 40mg tablet is involved in the effective treatment of mCRPC (metastatic castration resistant prostate cancer), taken orally. The effect of anti-androgen viewing by obstruct the testosterone production by inhibiting androgen synthesis, the hormone which is require for cancer cell growth. Enzamide 40mg is majorly used to treat prostate cancer in men.

• 

MECHANISM

The primary usage of  Enzamide 40mg tablet is involved in the effective treatment of mCRPC (metastatic castration resistant prostate cancer), taken orally. The effect of anti-androgen viewing by obstruct the testosterone production by inhibiting androgen synthesis, the hormone which is require for cancer cell growth. Enzamide 40mg is majorly used to treat prostate cancer in men.

DOSAGE

• The usual prescribed dosage of Enzamide is 160mg as a single dose by taking with or without food.
• Enzamide is available in the strength of 40mg; four tablets of  Enzamide 40mg  should be administered at a same time. Enzamide tablet should not crush, not chew taken with glass of water. Dose adjustment: In patients with ≥ grade III toxicity: 
• Enzamide 40mg therapy should be refuse for one week or the symptoms should be reduced to grade II, then restart with same dose or decreased to 80mg or 120mg Strong CYP2C8 inhibitors: While combining with  Enzamide 40mg tablet , the dosage should be modified by reducing to 80mg as a single dose or avoid this combination. Strong CYP3A4 inducers: Co administration of  Enzamide 40mg with Strong CYP3A4 inducers, the dosage of Enzamide tablet increased up to 240mg or stop this combination.

WARNING AND PRECAUTIONS

During the treatment with  Enzamide 40mg tablets, patient may suffer with some adverse effects like; Posterior reversible encephalopathy syndrome Seizures In PRES, some neurological disorders occur in patients. The condition can recovered by providing safety measures or discontinue the therapy as soon as possible. PRES is recognized by using MRI In seizures, Before starting the treatment patient must counsel about this adverse reaction and Stop the therapy if possible. Spermatogenesis occurs that may prohibit the male fertility leads to hypo spermatogenesis. In androgen decline the treatment, may have increase exposure of cardiovascular disease like worsening hypertension.

Enzamide 40MG INTERACT WITH SOME DRUGS LIKE

• Enzamide 40mg combined with CYP2C8 strong inhibitors, causes elevation of plasma concentration time curve of Enzalutamide and its active metabolite. So avoid this combination, otherwise dosage of Enzamide should be reduced to 80mg.
•   Enzamide 40mg with CYP2C8 strong inducers causes variation in plasma exposure of Enzamide, to minimize this problem to avoid this concomitant. Co administration of  Enzamide 40mg tablet with strong inhibitors or CYP3A4, leads to elevate the AUC of Enzalutamide and its metabolite. CYP3A4 strong inducers example like; phenytoin, Phenobarbital, carbamazepine etc combines with Enzamide tablets causes depletes the plasma exposure of  Enzamide 40mg .
• Moderate CYP3A4 inducers like Bosentan, efavirenz, modafinil, st Johns wort causes decreasing the plasma concentration of Enzamide tablet. 
• Enzamide 40mg tablet are strong CYP3A4 inducers and moderate CYP2C8 & CYP2C19. CYP3A4 strong inducers like Midazolam, CYP2C8 inducers like warfarin, & CYP2C19 inducers like Omeprazole with Enzamide 40mg causes reducing the plasma risk of Midazolam, warfarin & Omeprazole.

MISSED DOSE

• Enzamide 40mg is a chem. Drug, used in prostate cancer. 
• Enzamide 40mg tablet should not be self medicated, used by the patients only after getting advice from the medical oncologist.
• If a single dose missed by patient, then must consult with the physician and follow the instructions as per the guidance of medical adviser, the missed dose should be taken within a time or avoid the missed dose and follow the regular schedule.

CONTRAINDICATION

Enzamide 40mg tablet are contraindicated to pregnancy condition, which may cause fetal harm leads to death. An Anaphylactic reaction happens, if patients are contraindicated to the ingredient present in Enzamide tablets.

OVER DOSAGE

In the case of over dosage of  Enzamide 40mg tablet , causes severe seizures. If occurring of over dosage , immediately discontinue the treatment and maintain the safety measures. In dose acceleration study at ≤ 240mg daily the condition seizure does not occur. If the dose of 360mg, 480mg & 600mg at high risk will causes Seizures

SIDE EFFECTS

Some side effects during the therapy using with Azel; Back pain, Arthralgia, Muscular weakness, pain, Diarrhea, Hypertension & hot flush, Dizziness, headache, Asthenia conditions, Peripheral edema, Spinal cord compression, paresthesia, Mental impairment, Hypesthesia, Respiratory tract infections, Hematuria, Pollakiuria, Dry skin, Pruritus, Neutropenia, Thrombocytopenia, Increasing bilirubin level, Epistaxis, Infections like sepsis, Fractures, joint injury, and hematomas (Fall associated injuries). Hallucinations .

STORAGE

Enzamide 40mg tablet container should be stored at the temperature of 20℃ to 25℃ (68℉ to 77℉). Keep the container in cool and dry place Protect from light.

PREGNANCY

Pregnancy category of  Enzamide 40mg tablet is D Enzamide is contraindicated to pregnancy; it may cause fetal harm even to death.

CONTACT DETAILS

Phone : 9987711567

Email : applepharmaceutical@gmail.com

Email : info@myapplepharma.com

Website : https://myapplepharma.com/enzamide-40mg.php#

https://myapplepharma.com/enzalutamide.php

Glenza 40mg is a hormonal therapy, for men who are all affected with prostate carcinoma in metastaic stage.Glenza 40mg Capsules are majorly indicated for prostate carcinoma, which contains Enzalutamide, as an active component considered as non steroidal anti-androgen medication. Glenza 40mg is involved in association with castration in the therapy of metastatic or long lasting castration resistant prostate cancerGlenza 40mg is a prescription medicine, the main ingredient which is used as enzalutamide, only prescribed by medical oncologist.

CAPSULES INDICATIONS

The primary usage of Glenza 40mg Capsule is involved in the effective treatment of mCRPC (metastatic castration resistant prostate cancer), taken orally. The effect of anti-androgen viewing by obstruct the testosterone production by inhibiting androgen synthesis, the hormone which is require for cancer cell growth.Glenza 40mg is majorly used to treat prostate cancer in men.

MECHANISM

An androgen which is a male hormone is used to develop prostate carcinoma. One of the major hormone secreted by testes and adrenal glands is known as testosterone. Glenza 40mg containing Enzalutamide will interfere with testosterone production, causes tumor cell growth depletion. Glenza 40mg interfere with androgen receptor signaling transduction and leads to cancer cell lysis

PHARMACOKINETICS

Absorption: 
After receiving 160mg of Glenza 40mg for mCRPC, from median time to attain peak plasma concentration time at 1 hour (variation with 0.5 to 3 hours). The steady state level of Glenza 40mg is accomplished by day 28 Food does not cause any alteration in absorption of Glenza Capsuless. 

Distribution: 
Volume of distribution 110L High plasma protein bounding capacity of Glenza 40mg Capsule  is occurs as 97% to 98% 

Metabolism: 
Two most prominent cytochrome isoenzymes are involved in metabolism of Glenza Capsuless; There are two isoenzymes i.e CYP2C8 & CYP3A4; in which CYP2C8 is vital for production of N-desmethyl Enzalutamide which is an active metabolite of Enzalutamide. 

Excretion: 
Glenza 40mg Capsule undergoes excretion by hepatic metabolism Major route of elimination; 71% in urine; 14% in feces The terminal half life period of Glenza Capsuless is 5.8 days (range at 2.8 to 10.2 days); N-desmethyl Enzalutamide has half life period of relatively 7.8 to 8.6 days.

DOSAGE

DOSING CONDITIONS AND ADMINISTRATION
The usual prescribed dosage of Glenza 40mgis 160mg as a single dose by taking with or without food. Glenza is available in the strength of 40mg; four Capsuless of Glenza 40mgshould be administered at a same time. GlenzaCapsules should not crush, not chew taken with glass of water. Dose adjustment: In patients with ≥ grade III toxicity: Glenza 40mg therapy should be refuse for one week or the symptoms should be reduced to grade II, then restart with same dose or decreased to 80mg or 120mg Strong CYP2C8 inhibitors: While combining with Glenza Capsules, the dosage should be modified by reducing to 80mg as a single dose or avoid this combination. Strong CYP3A4 inducers: Co administration of Glenza with Strong CYP3A4 inducers, the dosage of Glenza Capsules increased up to 240mg or stop this combination.

WARNING AND PRECAUTIONS

During the treatment with Glenza 40mg , patient may suffer with some adverse effects like; Posterior reversible encephalopathy syndrome Seizures In PRES, some neurological disorders occur in patients. The condition can recovered by providing safety measures or discontinue the therapy as soon as possible. PRES is recognized by using MRI In seizures, Before starting the treatment patient must counsel about this adverse reaction and Stop the therapy if possible. Spermatogenesis occurs that may prohibit the male fertility leads to hypo spermatogenesis. In androgen decline the treatment, may have increase exposure of cardiovascular disease like worsening hypertension.

DRUG INTERACTION

Glenza 40mg combined with CYP2C8 strong inhibitors, causes elevation of plasma concentration time curve of Enzalutamide and its active metabolite. So avoid this combination, otherwise dosage of Glenza should be reduced to 80mg. Glenza 40mgwith CYP2C8 strong inducers causes variation in plasma exposure of Glenza 40mg, to minimize this problem to avoid this concomitant. Co administration of Glenza Capsuless with strong inhibitors or CYP3A4, leads to elevate the AUC of Enzalutamide and its metabolite. CYP3A4 strong inducers example like; phenytoin, Phenobarbital, carbamazepine etc combines with Glenza Capsuless causes depletes the plasma exposure of Glenza. Moderate CYP3A4 inducers like Bosentan, efavirenz, modafinil, st Johns wort causes decreasing the plasma concentration of Glenza Capsules. Glenza Capsuless are strong CYP3A4 inducers and moderate CYP2C8 & CYP2C19. CYP3A4 strong inducers like Midazolam, CYP2C8 inducers like warfarin, & CYP2C19 inducers like Omeprazole with Glenza causes reducing the plasma risk of Midazolam, warfarin & Omeprazole.

MISSED DOSE

Glenza 40mg is a chem. Drug, used in prostate cancer. Glenza 40mg Capsule should not be self medicated, used by the patients only after getting advice from the medical oncologist. If a single dose missed by patient, then must consult with the physician and follow the instructions as per the guidance of medical adviser, the missed dose should be taken within a time or avoid the missed dose and follow the regular schedule

CONTRAINDICATION

Glenza 40mg Capsule are contraindicated to pregnancy condition, which may cause fetal harm leads to death. An Anaphylactic reaction happens, if patients are contraindicated to the ingredient present in Glenza 40mg Capsule.

SIDE EFFECTS

Some side effects during the therapy using with Glenza; Back pain, Arthralgia, Muscular weakness, pain, Diarrhea, Hypertension & hot flush, Dizziness, headache, Asthenia conditions, Peripheral edema, Spinal cord compression, paresthesia, Mental impairment, Hypesthesia, Respiratory tract infections, Hematuria, Pollakiuria, Dry skin, Pruritus, Neutropenia, Thrombocytopenia, Increasing bilirubin level, Epistaxis, Infections like sepsis, Fractures, joint injury, and hematomas (Fall associated injuries). Hallucinations .

Lactation

Breast feeding is not suggested, Glenza is contraindicated in lactation

STORAGE

Glenza 40mg Capsule container should be stored at the temperature of 20℃ to 25℃ (68℉ to 77℉). Keep the container in cool and dry place Protect from light.

CONTACT DETAILS

Phone : 9987711567

Email : applepharmaceutical@gmail.com

Email : info@myapplepharma.com                                           

Website : https://myapplepharma.com/enzalutamide-40mg.php

https://myapplepharma.com/enzalutamide.php